세계의 당뇨병 치료용 임상 영양 시장 : 시장 규모 분석(제품별, 병기별, 판매 채널별, 지역별) 및 예측(2022-2032년)

Global Clinical Nutrition For Diabetes Care Market is valued at approximately USD 2.15 billion in 2023 and is anticipated to grow with a steady compound annual growth rate (CAGR) of 4.78% over the forecast period 2024-2032. In a world where lifestyle disorders continue to dominate public health discourse, the burden of diabetes-particularly Type 2 diabetes-has rapidly expanded into a full-blown global crisis. Within this context, clinical nutrition has emerged not merely as a supplemental intervention, but as a cornerstone in diabetes care management. It empowers both clinicians and patients to mitigate glycemic variability, preserve lean body mass, and support metabolic regulation with precision. Leveraging specially formulated enteral and parenteral solutions, the market is advancing toward customized nutritional protocols that meet the diverse physiological demands of diabetic individuals.

At the core of the market's growth is a sharpened clinical and consumer awareness about the pivotal role of nutrition in glycemic control and diabetes-related complication management. Healthcare providers are increasingly endorsing medical nutrition therapy as part of a comprehensive care model-encouraging patients to transition from reactive treatments to proactive disease modulation. Innovations in oral supplements and enteral formulations now feature bioengineered macronutrient profiles that align with diabetic patients' insulin sensitivity, energy metabolism, and satiety needs. Moreover, the integration of AI-driven diagnostic platforms is enabling practitioners to align dietary regimens with real-time biomarker feedback, marking a new era of nutrition-guided precision medicine.

Despite these technological advances, the market contends with systemic constraints such as the high cost of specialized nutrition products and limited reimbursement frameworks across several regions. In low- and middle-income countries, where diabetes incidence is rising steeply, accessibility to clinical nutrition remains restricted. Nonetheless, robust R&D investment pipelines, along with growing consumer inclination toward preventative healthcare solutions, are mitigating some of these structural challenges. Partnerships between nutraceutical brands and hospitals are further enhancing patient outreach, particularly through in-hospital education campaigns and post-discharge home care nutrition plans.

Sales channels are undergoing a quiet revolution, evolving from traditional brick-and-mortar hospital pharmacies toward diversified e-commerce platforms, enabling global distribution of specialized clinical nutrition products. Online availability is proving especially advantageous in chronic care management, where routine supply continuity is essential. Meanwhile, manufacturers are tailoring their go-to-market strategies by segmenting their offerings according to different stages of diabetes care-from pre-diabetic nutritional support to complex comorbidity formulations for advanced patients. This lifecycle-based segmentation fosters a high degree of brand stickiness and clinical reliance.

Regionally, North America commands the largest market share, underpinned by strong regulatory support, advanced healthcare infrastructure, and widespread diabetes education programs. The United States, in particular, leads in product innovation, driven by both industry and government-led initiatives for chronic disease mitigation. Europe follows with steady momentum, propelled by state-funded nutrition programs and a rapidly aging diabetic population. On the other hand, the Asia Pacific region is anticipated to witness the fastest growth rate due to surging diabetes prevalence, evolving dietary patterns, and increased investment in personalized healthcare technologies. Countries like China, India, and Japan are paving the way with proactive public-private initiatives aimed at integrating nutrition therapy into mainstream diabetes care.

Major market player included in this report are:

• Abbott Laboratories
• Nestle Health Science
• Danone S.A.
• Fresenius Kabi AG
• Baxter International Inc.
• B. Braun Melsungen AG
• Glanbia PLC
• Perrigo Company plc
• Otsuka Holdings Co., Ltd.
• Ajinomoto Co., Inc.
• Meiji Holdings Co., Ltd.
• Medtrition, Inc.
• Nutricia (a part of Danone)
• Hormel Foods Corporation
• Cambrooke Therapeutics, Inc.

The detailed segments and sub-segment of the market are explained below:

By Product

• Oral
• Enteral Feeding Formulas
• Parenteral Nutrition

By Stage

• Early-stage Diabetes
• Intermediate-stage Diabetes
• Advanced-stage Diabetes

By Sales Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Clinical Nutrition For Diabetes Care Market Executive Summary

• 1.1. Global Clinical Nutrition For Diabetes Care Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Product (Oral, Enteral Feeding Formulas, Parenteral Nutrition)
  • 1.3.2. By Stage (Early-stage, Intermediate-stage, Advanced-stage Diabetes)
  • 1.3.3. By Sales Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
• 1.4. Key Trends
• 1.5. Reimbursement & Policy Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Clinical Nutrition For Diabetes Care Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Manufacturing Capacity & Infrastructure
    • 2.3.3.2. Raw-material Availability
    • 2.3.3.3. Regulatory Environment & Standards
    • 2.3.3.4. Competitive Landscape
    • 2.3.3.5. Cost Structures & Pricing Dynamics
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Reimbursement Frameworks
    • 2.3.4.2. Clinical Guidelines & Physician Adoption
    • 2.3.4.3. Patient Awareness & Acceptance
    • 2.3.4.4. Technological Advances in Nutrition Therapy
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Clinical Nutrition For Diabetes Care Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Escalating Global Diabetes Prevalence
  • 3.1.2. Recognition of Malnutrition and Sarcopenia in Diabetic Patients
  • 3.1.3. Innovations in Tailored Nutrition Formulations
• 3.2. Market Challenges
  • 3.2.1. High Cost of Specialized Nutrition Products
  • 3.2.2. Limited Reimbursement and Insurance Coverage
• 3.3. Market Opportunities
  • 3.3.1. Expansion into Emerging Economies
  • 3.3.2. Growth of Digital Nutrition Platforms
  • 3.3.3. Personalized and Precision Nutrition Therapies

Chapter 4. Global Clinical Nutrition For Diabetes Care Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Forces
  • 4.1.7. Porter's 5 Forces Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economic
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top Investment Opportunity
• 4.4. Top Winning Strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Clinical Nutrition For Diabetes Care Market Size & Forecasts by Product 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Market: {Product} Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Oral
  • 5.2.2. Enteral Feeding Formulas
  • 5.2.3. Parenteral Nutrition

Chapter 6. Global Clinical Nutrition For Diabetes Care Market Size & Forecasts by Stage 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Market: {Stage} Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Early-stage Diabetes
  • 6.2.2. Intermediate-stage Diabetes
  • 6.2.3. Advanced-stage Diabetes

Chapter 7. Global Clinical Nutrition For Diabetes Care Market Size & Forecasts by Sales Channel 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Market: {Sales Channel} Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Hospital Pharmacies
  • 7.2.2. Retail Pharmacies
  • 7.2.3. Online Pharmacies

Chapter 8. Global Clinical Nutrition For Diabetes Care Market Size & Forecasts by Region 2022-2032

• 8.1. North America
  • 8.1.1. U.S. Market
    • 8.1.1.1. Product breakdown size & forecasts, 2022-2032
    • 8.1.1.2. Stage breakdown size & forecasts, 2022-2032
  • 8.1.2. Canada Market
• 8.2. Europe
  • 8.2.1. UK Market
  • 8.2.2. Germany Market
  • 8.2.3. France Market
  • 8.2.4. Spain Market
  • 8.2.5. Italy Market
  • 8.2.6. Rest of Europe Market
• 8.3. Asia Pacific
  • 8.3.1. China Market
  • 8.3.2. India Market
  • 8.3.3. Japan Market
  • 8.3.4. Australia Market
  • 8.3.5. South Korea Market
  • 8.3.6. Rest of Asia Pacific Market
• 8.4. Latin America
  • 8.4.1. Brazil Market
  • 8.4.2. Mexico Market
  • 8.4.3. Rest of Latin America Market
• 8.5. Middle East & Africa
  • 8.5.1. Saudi Arabia Market
  • 8.5.2. South Africa Market
  • 8.5.3. Rest of Middle East & Africa Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Abbott Laboratories
  • 9.1.2. Nestle Health Science
  • 9.1.3. Danone S.A.
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Abbott Laboratories
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Market Strategies
  • 9.3.2. Nestle Health Science
  • 9.3.3. Danone S.A.
  • 9.3.4. Fresenius Kabi AG
  • 9.3.5. Baxter International Inc.
  • 9.3.6. B. Braun Melsungen AG
  • 9.3.7. Glanbia PLC
  • 9.3.8. Perrigo Company plc
  • 9.3.9. Otsuka Holdings Co., Ltd.
  • 9.3.10. Ajinomoto Co., Inc.
  • 9.3.11. Meiji Holdings Co., Ltd.
  • 9.3.12. Medtrition, Inc.
  • 9.3.13. Nutricia (Danone)
  • 9.3.14. Hormel Foods Corporation
  • 9.3.15. Cambrooke Therapeutics, Inc.

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes